Browsing Tag
Moderna Inc.
2 posts
Moderna (MRNA) falls 18% despite melanoma win: Can an $81bn valuation hold?
Moderna shares plunged 17.57% despite positive Phase 3 melanoma data from its personalised mRNA cancer therapy developed with Merck. With an approximately $81 billion market valuation, continued operating losses and a commercial opportunity extending well beyond melanoma, the central question is how much future oncology success investors have already priced in.
Regencell Bioscience, D-Wave, Akero lead U.S. gainers as market shrugs off rate jitters
U.S. stocks surged May 20 led by Regencell, D-Wave, and Akero as tech and biotech outperformed amid inflation worries. Read the full market breakdown now.